Zydus Cadila has got the US health regulator’s final approval to market Voriconazole tablets that are used to treat fungal infections in the American market.

Cadila Healthcare has said in a BSE filing that “the Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Voriconazole tablets in strengths of 50 and 200 mg.”

The drug is going to be produced at the groups formulations manufacturing facility at Baddi (Himachal Pradesh).

Read EquityPandit’s Technical Analysis on Nifty Pharma